Hyperglycemia News and Research

RSS

Hyperglycemia occurs when you have a higher than usual level of glucose in your blood. This can happen shortly after you have eaten a big meal and is not a problem if your glucose level returns to normal. Cells remove glucose from the blood in response toinsulin. If your pancreas doesn't make enough insulin, glucose can't enter the cells and remains in the blood. Blood glucose levels can also get too high if cells areunable to respond to insulin properly (insulinresistance). Without glucose, your cells are unable to make energy and can't function properly.

Harmless plant extract can help treat Cushing Disease

Cushing Disease, not to be confused with Cushing's Syndrome, is caused by a tumour in the pituitary gland in the brain. The tumour secrets increased amounts of the stress hormone adrenocorticotropin (ACTH) followed by cortisol release from the adrenal glands leading to rapid weight gain, elevated blood pressure and muscular weakness.

16 Feb 2015

Scientists reveal genetic links to metabolic disorders

For at least 40 years, scientists who study how the body metabolizes sugar have accepted one point: there are four enzymes that kick-start the body's process of getting energy from food.

5 Feb 2015

Saint Louis University researchers find way to prevent type I diabetes in animal model

In new research published in Endocrinology, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal model.

21 Jan 2015

Novo Nordisk gets positive CHMP opinion for expanded use of Tresiba in children with diabetes

Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba® (insulin degludec) in children and adolescents aged one to 17 years with diabetes.

From Novo Nordisk 22 Dec 2014

FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration approved the intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi). Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.

19 Dec 2014

Continued exposure to high blood sugars may impact brain function in young diabetic children

Investigators have found that young children with type 1 diabetes (T1D) have slower brain growth compared to children without diabetes. A new study, published in the December issue of Diabetes, now available ahead of print, suggests that continued exposure to hyperglycemia, or high blood sugars, may be detrimental to the developing brain.

19 Dec 2014

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option.

16 Dec 2014

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition.

9 Dec 2014

Closed-loop artificial pancreas system improves diabetes management in adolescents

Research shows that the use of an artificial pancreas system helps to compensate for omission and underestimation of insulin boluses in adolescents with Type 1 diabetes.

1 Dec 2014

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen Research & Development, LLC today announced the submission of a New Drug Application (NDA) for three-month atypical antipsychotic paliperidone palmitate to the U.S. Food and Drug Administration. The NDA seeks approval for the medication as a treatment for schizophrenia in adults.

19 Nov 2014

Hospital bed positioning can affect outcomes of stroke patients

During the first 24 hours after a stroke, attention to detail --such as hospital bed positioning -- is critical to patient outcomes.

31 Oct 2014

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim today announced that Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States.

8 Oct 2014

Managing diabetes and intensive exercise: an interview with Dr Rafael Castol, Team Novo Nordisk

Team Novo Nordisk is a professional cycling team that races at UCI Pro Continental level. It's the first ever team to be made up of athletes diagnosed with Type 1 diabetes. The team was created three years ago, and is part of the Changing Diabetes initiative developed by Novo Nordisk.

From Novo Nordisk 1 Oct 2014

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).

30 Sep 2014

Hyperglycemia News and Research

Further Reading

Harmless plant extract can help treat Cushing Disease

Scientists reveal genetic links to metabolic disorders

Saint Louis University researchers find way to prevent type I diabetes in animal model

Novo Nordisk gets positive CHMP opinion for expanded use of Tresiba in children with diabetes

FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

Continued exposure to high blood sugars may impact brain function in young diabetic children

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Closed-loop artificial pancreas system improves diabetes management in adolescents

Janssen announces submission of NDA for three-month paliperidone palmitate

Hospital bed positioning can affect outcomes of stroke patients

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Managing diabetes and intensive exercise: an interview with Dr Rafael Castol, Team Novo Nordisk

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

Lilly and Boehringer Ingelheim's insulin glargine product gets marketing approval from EC

UT Southwestern researchers discover crucial link between high insulin levels and obesity pathways

Diabetes linked to increased head and neck cancer risk

Tree nuts have positive impact on glycemic control in diabetes and on metabolic syndrome criteria

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News